Gelonghui, Feb. 28, 丨 Nanxin Pharmaceutical (688189.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 744 million yuan, an increase of 6.50% over the same period of the previous year; achieved operating profit of 7.5947 million yuan, achieved a total profit of 6.9344 million yuan, and realized net profit attributable to shareholders of listed companies of 3,5477 million yuan, turning a loss into a profit over the previous year. As of December 31, 2023, the company's total assets were 1725.9855 million yuan, a decrease of 11.66% over the same period of the previous year; owners' equity attributable to the parent company was 1317.912,200 yuan, an increase of 0.27% over the same period of the previous year; and the net assets per share attributable to the owners of the parent company were 4.80 yuan, a decrease of 28.46% over the same period last year.